• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

dabigatran etexilate - Articles and news items

Boehringer Ingelheim logo

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years

Industry news / 19 November 2013 / Boehringer Ingelheim

Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention…

Boehringer Ingelheim logo

Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin

Industry news / 7 October 2013 / Boehringer Ingelheim

Post-hoc analysis demonstrates better survival prognosis following a major bleeding with Pradaxa® than with warfarin…

Boehringer Ingelheim logo

Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases

Industry news, News / 3 September 2013 / Boehringer Ingelheim

Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®…

Boehringer Ingelheim logo

ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations

Industry news, News / 26 August 2013 / Boehringer Ingelheim

Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013…

Boehringer Ingelheim logo

Application submitted to the EMA for use of Pradaxa® in treatment of DVT and PE and prevention of recurrent DVT and PE

Industry news / 24 June 2013 / Boehringer Ingelheim

Boehringer Ingelheim announced the submission of an application to the EMA…

Boehringer Ingelheim logo

New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF

Industry news, News / 17 June 2013 / Boehringer Ingelheim

New long-term data from the RELY-ABLE® study…

Boehringer Ingelheim logo
Boehringer Ingelheim logo
Boehringer Ingelheim logo

RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa®

Industry news, News / 8 November 2012 / Boehringer Ingelheim

Pivotal data from the RELY-ABLE® study have provided additional data…

Boehringer Ingelheim logo
Boehringer Ingelheim logo

FDA and EMA reaffirm important health benefits and safety of Pradaxa® for patients with atrial fibrillation

Industry news, News / 5 November 2012 / Boehringer Ingelheim

“We welcome the positive conclusions reached…”

Boehringer Ingelheim logo

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +